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Abstract
Background: Self-reported data are a common source of information about drug exposure.
Modes of data collection differ considerably and the questionnaire's structure may affect prevalence
estimates. We compared the recall of medication use evaluated by means of two questionnaires
differing in structure and length.
Methods: Drug utilization was assessed by two alternative versions of a questionnaire (A – 4
pages, including specific questions for 12 indications/pharmacological groups and one question for
"other medicines"; B – 1 page, including 1 open-ended question to cover overall drug consumption).
Each of 32 classes in a private University in Maputo, Mozambique, was randomly assigned
questionnaire A (233 participants) or B (276 participants). Logistic regression (allowing for
clustering by classroom) was used to compare the two groups in terms of socio-demographic
characteristics and medication used during the previous month.
Results: Overall, 67.4% of the subjects had used at least one drug during the previous month. The
following prevalences were greater among participants completing questionnaire A: use of drugs
from two or more pharmacological groups (60.5% vs. 34.4%, p < 0.001), use of two or more drugs
(66.2% vs. 43.0%, p < 0.001), and use of antibiotics (14.6% vs. 6.9%, p = 0.001), antifungals (9.4% vs.
4.0%, p = 0.013), antiparasitics (5.6% vs. 1.8%, p = 0.031) and antacids (8.6% vs. 3.6%, p = 0.024).
Information about duration of treatment and medical advice was more complete with version A.
Conclusion:  The indication/drug-specific questions (questionnaire A) revealed a significantly
higher prevalence of use of medicines – antibiotics, antifungals, antiparasitics and antacids – without
compromising the completeness of the information.
Background
Self-reported data are a common source of drug exposure
information [1-4] and in many settings they provide the
only method available for characterizing the use of medi-
cines [5].
Modes of data collection by questionnaire may differ in
several ways, including the methods for contacting
respondents and for questionnaire delivery, and the
administration of questions (e.g. the appearance of the
questionnaire, the language used and the cultural adapta-
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tion and wording). These differences may affect the relia-
bility and validity of the method [6-8].
Regarding drug utilization, questionnaire characteristics
such as question wording and question or response order
or format can be variously associated with exposure mis-
classification. Studies addressing the effect of question-
naire design on the recall of pharmacological treatments
are heterogeneous in aim, method and quality, but are
unanimous in concluding that indication- or drug-ori-
ented questions reveal higher prevalences of drug utiliza-
tion than open-ended questions [9]. However, obtaining
data related to various drug categories frequently requires
lengthy questionnaires including separate questions for
each of the main pharmaceutical groups under study. It
may not be possible or desirable to use large number of
questions for this purpose, as that may substantially
increase the size of the questionnaire and lead to poor
acceptability and participant compliance. A short ques-
tionnaire may have the advantages of lower respondent
burden and lower administrative costs, but its ability to
characterize drug utilization fully is expected to be more
limited. Shorter questionnaire versions can hardly include
specific questions about the different pharmacological
groups being assessed, which may compromise recall, and
the potential for a lower burden may be attenuated by the
use of more complex questions or a less attractive appear-
ance, with many questions concentrated in a small area
[10,11].
We hypothesized that a single-item questionnaire com-
plemented with examples of the indications and medi-
cines that are expected to be more frequent in the
population studied could yield similar estimates of the
prevalence of drug utilization to an extended multi-item
questionnaire addressing the utilization of medicines for
several indications. Therefore, our aim was to compare
recall using two questionnaires differing in structure and
length (long questionnaire including indication/drug-
specific questions vs. short questionnaire including one
open-ended question and several examples of indications
and drugs).
Methods
Students enrolled at a private University in Maputo,
Mozambique were investigated in April 2007. Socio-
demographic details and information regarding the drugs
used during the previous month (when applicable) were
collected using a self-administered questionnaire pre-
sented to all diurnal classes, with the consent of the teach-
ers. The questionnaire was given to all the students
present in each class. No attempt was made to contact
those who were absent. Ten students (1.9% of all invited)
refused to participate (1.7% of those receiving question-
naire A and 2.1% of those receiving questionnaire B) and
509 were evaluated, approximately 50% of the total
number of students in the institution who were enrolled
in diurnal classes (Figure 1).
Two alternative versions (A and B) of the questionnaire,
differing in question structure and length, were used to
collect information. Both versions started with the same
close-ended question "Did you use any medication in the last
month (including tablets, capsules, injections, ointments,
ovules, syrups, etc.)?" and gave similar general instructions
to the participants. The questionnaires answered by the
participants (versions A and B) were in Portuguese. Eng-
lish versions are provided as additional files 1 and 2.
Questionnaire A (see additional file 1: questionnaire A) was
4 pages long and included separate questions, with exam-
ples of specific drugs or medicines, for each of 12 indica-
tions/pharmacological groups, and one additional
question for "other medicines" (see table 1). Subjects
were asked to complete an open-ended table for each
group, with the following information for each drug/med-
icine: brand or generic name, duration of treatment, med-
ical advice and intended purpose. The indications/
pharmacological groups for which specific questions were
asked in questionnaire A and the examples given to the
participants were selected from the medicines most fre-
quently consumed by this population, as observed in a
previous survey in the same setting [12]. The order of the
questions in questionnaire A took into account the fre-
quency of consumption (the most frequently-consumed
medicines were the first to be asked about) and the simi-
larity of indications/pharmacological groups (e.g.
although antimalarial drugs were rarely consumed during
the previous month, the question about them was placed
near questions about the use of other anti-infectious
drugs).
Questionnaire B (see additional file 2: questionnaire B) was
one page long and included a single open-ended question
to cover overall drug consumption, preceded by a short
passage of text including the same examples provided in
each of the questions from questionnaire A. Subjects were
asked to complete a table similar to the ones described for
questionnaire A.
Each medicine mentioned in questionnaires A or B was
coded to the second level of classification (therapeutic
subgroup) of the WHO Anatomical Therapeutic Chemical
classification (ATC) [13]. The pharmacological groups/
indications for which there were specific questions in
questionnaire A and the corresponding ATC subgroups
are shown in table 1. For data analysis, the medicines clas-
sified as "medications for treatment of pain and inflam-
mation" or as "medications for treatment of flu or cold"
were considered jointly as "analgesics".BMC Medical Research Methodology 2009, 9:45 http://www.biomedcentral.com/1471-2288/9/45
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Information about medical advice (to assess the use of
medication following recent or past medical advice) and
duration of treatment was analysed separately for drugs
from each pharmacological group. For subjects using
more than one medicine in the same group, the mean
duration of treatment was used for analysis. For each
pharmacological group, the results regarding medical
advice are presented as the percentage of subjects who had
used at least one medicine under a physician's advice.
To test the hypothesis that the two differently-structured
questionnaires yielded the same prevalence of drug utili-
zation, one version was randomly assigned to each of the
32 diurnal classes using a list of random numbers gener-
ated with EPi Info software, version 6.04d [14]. Question-
naires A and B were designated to 14 and 18 classes,
respectively. All subjects within the same classroom
received the same questionnaire version (A: 233 subjects;
B: 276 subjects).
The choice of a one-month recall period was based on the
expected frequency of drug utilization in this population,
which was informed by a previous survey in the same set-
ting [12]. This sample allows differences in the estimates
of the two questionnaires to be detected with a power of
80%, for a 95% confidence level, when the magnitude of
the difference corresponds to a risk ratio of two, and the
proportion of drug use is above 10%, considering a design
effect as high as 1.15 (which would be obtained for an
average cluster size of 15 and an intra-cluster correlation
coefficient of 0.01) [15]. The assumptions about the
expected design effect and average cluster size are sup-
ported by a previous similar study in the same setting
[16].
Logistic regression with robust standard errors (allowing
for clustering by classroom) was used to compare the two
groups (questionnaire A and questionnaire B) in terms of
socio-demographic characteristics and medication used
during the previous month [17]. All the tables present p-
values corresponding to comparisons with no adjustment
of covariates. The groups of medicines are presented in the
tables in the order in which they appeared in Question-
naire A. Data were analyzed using STATA®, version 9.2.
Flowchart of the sampling strategies Figure 1
Flowchart of the sampling strategies.BMC Medical Research Methodology 2009, 9:45 http://www.biomedcentral.com/1471-2288/9/45
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The National Ethics Committee of Mozambique
approved the survey protocol. Students were asked to read
an informed consent form stating the general objectives of
the study and data collection methods, in agreement with
the Declaration of Helsinki. Only students who signed the
informed consent form were allowed to participate and
were asked to complete the questionnaire.
Results
There were no statistically significant differences in the
characteristics of the participants answering question-
naires A or B in terms of socio-demographic characteristics
or the percentage of subjects who had used at least one
medicine during the previous month (67.4% in both
questionnaire versions) (Table 2).
The median number of different pharmacological groups
used by each subject (2 vs. 1), and the percentage of par-
ticipants reporting the use of drugs from two or more
pharmacological groups, were higher among those com-
pleting questionnaire A (60.5% vs. 34.4%, p < 0.001).
Also, questionnaire A revealed a greater median number
Table 1: Indication/Pharmacological groups and examples presented in both questionnaire versions, and subsequent classification 
according ATC nomenclature.
Indication/Pharmacological group Examples Classification (level II ATC subgroups)
Medications for treatment of pain and 
inflammation
Paracetamol, Voltaren®/diclofenac, ibuprofen, 
etc.
Analgesics (M01: Anti-inflammatory and anti-
rheumatic drugs, non steroids, N02: Analgesics, 
B01: Antithrombotic agents)
Medications for treatment of flu or cold Cêgripe®, Constipal®, Corenza® C Analgesics
Antibiotics amoxicillin, tetracycline, co-trimoxazol, 
metronidazol, etc.
Antibiotics 
(J01: Antibacterials for systemic use)
Antimicotics/antifungals for treatment of 
infections
Canesten®, Clotrimazol®, Quadriderme®, 
Nalbix®, etc
Antifungals (ATC D01: Antifungals for 
dermatological use; G01: Gynecological 
antiinfectives and antiseptics; D07: 
Corticosteroids, dermatological preparations, 
combinations with antibiotics, J02: Antimicotics 
for systemic use)
Antimalarials artemisine + fansidar®, etc Antimalarials (ATC P01B: Antimalarials)
Antiparasitics albendazol, mebendazol, etc Antiparasitics 
(P01, except P01B: Antiprotozoals; P02: 
Antihelmintics)
Vitamins and minerals multivitamins, complex B, ferrous salt, vitamin 
C, etc.
Vitamins 
(ATC A11: Vitamins, B03: Antianemic 
preparations)
Antiasthmatics salbutamol/Ventilan®, aminofiline, 
beclomethasone, prednisolone, etc.
Antiasthmatics (R03: Drugs for obstructive 
airway diseases, H02: CCT for systemic use
Antihistamines clorfeniramine, loratadine, Claritine®, etc.), Anti-histamines 
(ATC R06: Antihistamines for systemic use)
Oral contraceptives/«pill» Diane® 35, Microginon®, etc. Hormonal contraceptives for systemic use 
(ATC G03: Sex hormones and modulators of 
the genital system; L02: Endocrine Therapy)
Antitussives and/or expectorants Benilyn®, Diacol®, Benetussin®, Tosseque®, 
sodium benzoate, etc.
Antitussives 
(ATC R05: Cough and cold preparations)
Medications for gastric problems omeprazole, cimetidine, ranitidine, ENO®- fruit 
salts, aluminium hydroxide, Rennie®, 
Kompensan®, etc.
Antacids 
(ATC A02: Drugs for acid related disorders)
Others including all the drugs not included in the 
previously-described groupsBMC Medical Research Methodology 2009, 9:45 http://www.biomedcentral.com/1471-2288/9/45
Page 5 of 9
(page number not for citation purposes)
of medicines used per person among drug users (2 vs. 1)
and a greater percentage of participants reporting the use
of two or more drugs (66.2% vs. 43.0%, p < 0.001). How-
ever, the median number of drugs reported for all groups
was 1 in both questionnaires, except for antimalarials (A
vs. B: 2 vs.1).
Participants completing questionnaire A recalled use of
the following drugs more frequently: antibiotics (14.6%
vs. 6.9%, p = 0.001), antifungals (9.4% vs. 4.0%, p =
0.013), antiparasitics (5.6% vs. 1.8%, p = 0.031) and ant-
acids (8.6% vs. 3.6%, p = 0.024). However, no statistically
significant differences were observed for the remaining
drug groups (Table 3).
When the data were analysed separately for males and
females, the relationship between the prevalences of drug
use were essentially the same for both sexes (Table 4).
The proportion of subjects who did not provide informa-
tion about the duration of previously reported treatments
differed across pharmacological groups, but tended to be
much higher among participants completing question-
naire B. The duration of treatment reported by the partic-
ipants ranged from 1 day for antimalarials and 2 days for
analgesics to 15 days for antiasthmatics and 1 month for
oral contraceptives (Table 5).
The proportion of subjects who did not provide informa-
tion about treatment under medical advice during the pre-
ceding month differed across pharmacological groups,
but tended to be much higher among participants com-
pleting questionnaire B. There were also clear differences
in the percentage of subjects who received treatment
under medical advice, but no systematic differences were
observed according to the questionnaire used (Table 6).
Discussion
The longer questionnaire version, which included indica-
tion/drug-specific questions, revealed a significantly
higher prevalence of use of antibiotics, antifungals/antim-
icotics, antiparasitics and antacids. For the remaining drug
groups, recall did not differ significantly between ques-
tionnaire versions. Participants receiving the question-
naire version relying on a single open-ended question
tended to provide less complete information about treat-
ment duration and medical advice.
The differences in the estimates obtained with the two
questionnaire versions were not the same across all phar-
macological groups or drugs. This is consistent with previ-
ous finding in studies addressing the effect of
questionnaire design on the recall of pharmacological
treatments [16,18,19].
Ademi et al. [20] tested different question formats (fre-
quency measure; symptom-oriented question; open-
ended question), in a substantially different population,
to quantify the prevalence of use of analgesics during the
preceding seven days. The higher prevalence was obtained
by asking the respondents to name the medicines they
had used during the previous week, but the open-ended
item was the last of three questions asked sequentially.
For antibiotics and antifungals/antimicotics the estimated
prevalence differed significantly between the two ques-
tionnaire structures. This was also noted by Neutel et al.
[19] who observed that antibiotics were better recalled
when asked about by specific name rather than by drug
category. Our study revealed no differences between the
two questionnaire versions in assessing antimalarials,
which may be because malaria is a very frequent severe
disease in this setting, so we would not expect the partici-
pants to forget malaria treatments used within one month
of the interview.
For pharmacological groups such as the antiasthmatics,
no differences between questionnaire versions were
observed in the prevalence of use, perhaps because these
drugs are used to treat a chronic condition, unlikely to be
Table 2: Characteristics of participants evaluated using questionnaires A (14 classrooms, 233 subjects) and B (18 classrooms, 276 
subjects).
Questionnaire
Number of subjects* A
n (%)
B
n (%)
P
Age (% above 20) 489 101 (44.9) 103 (39.0) 0.557
Sex (% male) 497 80 (35.2) 104 (38.5) 0.728
Study area (% health related) 509 77 (33.0) 88 (31.9) 0.949
Grade (% above 2nd grade) 509 133 (57.1) 111 (40.2) 0.404
Users of at least one medicine during the previous month 509 157 (67.4) 186 (67.4) 0.999
* The number of subjects may differ between the variables owing to missing data.BMC Medical Research Methodology 2009, 9:45 http://www.biomedcentral.com/1471-2288/9/45
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forgotten by the participants, and recalled regardless of
the questionnaire format used. For vitamins or antitus-
sives, the differences observed were not significant but
were consistent in men and women, suggesting that the
recall may again be affected by the differences in question-
naire design.
The population evaluated in our study was relatively
homogeneous in age and education and does not ade-
quately represent Mozambican university students, still
less the general population. Studies assessing the influ-
ence of education on recall in drug utilization have con-
cluded that agreement between questionnaires and
information retrieved from record data increases with
education [21,22], although less educated subjects tend to
use medicines more than better educated ones [1]. We
may expect even greater differences between the results
obtained with versions A and B of the questionnaire
among older or less well-educated participants. The
results from surveys based on self-reporting of drug intake
among such populations need an even more cautious
interpretation.
The internal validity of the present study is not compro-
mised by our option for a one-month recall period, since
it applied to both the questionnaire versions compared.
Choosing a shorter recall period (e.g. two days or a week)
would have contributed to more accurate recall of the
medicines to which the participants had been exposed,
but also to a lower prevalence of use. Conversely, a longer
recall period (e.g. six months or one year) would have
yielded worse recall [23] but a higher proportion of sub-
jects using medicines. Regarding external validity, we may
expect a structured questionnaire with specific questions
about indication/pharmacological group to have more
impact on the recall of medicines used for acute condi-
tions, but a negligible impact when recall is only required
over shorter periods.
Both groups (A and B) answered the questionnaire at the
same time, so seasonal fluctuations on the intake of med-
icines for flu symptoms or malaria cannot be expected to
have compromised internal validity. It may not be possi-
ble to generalize our results to studies conducted at other
times of the year since the differences between question-
naire's versions may be related to the frequency of con-
sumption of medicines used for seasonally variable
conditions. We think it is unlikely that the recall of
malaria treatment would be substantially influenced by
questionnaire design, given the severity of the disease. For
Table 3: Medication used during the previous month, according 
to the type of questionnaire (n = 509).
Questionnaire
A
n (%)
B
n (%)
P
Analgesics 114 (48.9) 127 (46.0) 0.634
Antibiotics 34 (14.6) 19 (6.9) 0.001
Antifungals 22 (9.4) 11 (4.0) 0.013
Antiparasitics 13 (5.6) 5 (1.8) 0.031
Antimalarials 3 (1.3) 5 (1.8) 0.690
Vitamins 38 (16.3) 28 (10.1) 0.118
Antiasthmatics 7 (3.0) 10 (3.6) 0.666
Antihistamines 34 (14.6) 34 (12.3) 0.362
Contraceptives * 14 (9.5) 14 (8.4) 0.742
Antitussives 6 (2.6) 2 (0.7) 0.118
Antacids 20 (8.6) 10 (3.6) 0.024
Other drugs 22 (8.0) 18 (7.7) 0.922
* Information on the use of contraceptives refers only to the female 
participants.
Table 4: Medication used by women and men during the previous month, according to the type of questionnaire.
Women (n = 313) Men (n = 184)
Questionnaire Questionnaire
A
n (%)
B
n (%)
PA
n (%)
B
n (%)
P
Analgesics 75 (51.0) 88 (53.0) 0.795 37 (46.2) 38 (36.5) 0.109
Antibiotics 21 (14.3) 12 (7.2) 0.007 11 (13.8) 7 (6.7) 0.186
Antifungals 14 (9.5) 7 (4.2) 0.013 7 (8.8) 4 (3.8) 0.115
Antiparasitics 12 (8.2) 3 (1.8) 0.002 1 (1.2) 2 (1.9) 0.685
Antimalarials 2 (1.4) 5 (3.0) 0.445 1 (1.2) 0 (0.0) ---
Vitamins 28 (19.0) 22 (13.2) 0.282 9 (11.2) 5 (4.8) 0.111
Antiasthmatics 6 (4.1) 6 (3.6) 0.812 1 (1.2) 4 (3.8) 0.325
Antihistamines 23 (15.6) 22 (13.2) 0.541 10 (12.5) 12 (11.5) 0.802
Antitussives 3 (2.0) 1 (0.6) 0.268 3 (3.8) 1 (1.0) 0.220
Antacids 17 (11.6) 8 (4.8) 0.048 3 (3.8) 2 (1.9) 0.322
Other drugs 13 (8.8) 10 (6.0) 0.316 3 (3.8) 4 (3.8) 0.977BMC Medical Research Methodology 2009, 9:45 http://www.biomedcentral.com/1471-2288/9/45
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the remaining pharmacological groups used for acute con-
ditions, our results do not suggest differences dependent
on the frequency of consumption, beyond random varia-
tion. Also, the enhanced recall of drug utilization
obtained using indication- and drug-oriented questions
seems to be independent of the frequency of drug use
[18].
The specificity of the questions about pharmacological
treatments is known to contribute to more accurate esti-
mates of medicine use [9]. However, since it is not feasible
to write all possible examples of medicines for each indi-
cation/pharmacological group, recall may differ between
the examples provided and medicines that are not listed.
We tried to overcome this limitation by asking simultane-
ously about the use of medicines for specific indications/
pharmacological groups and providing examples of the
medicines most commonly used in this population.
Moreover, the same sets of examples were used in both
versions to ensure comparability in this aspect of ques-
tionnaire design.
Since the same medicine can be used for different pur-
poses, respondents may become confused about how to
respond when indications and example medicines are
provided side by side. This is particularly important for
drugs such as paracetamol, which may be used both for
"pain and inflammation" and for symptomatic "treat-
ment of flu or cold". We opted to use two separate ques-
tions for these indications, expecting to improve recall,
and asked participants for the intended utilization of each
medicine, allowing them to be classified correctly in this
regard. In addition, although we had two separate ques-
tions for medicines used for "pain and inflammation" and
Table 5: Information about the duration of treatment with medication used during the previous month, according to the type of 
questionnaire.
Missing information regarding
duration of treatment, n (%)
Median duration
of treatment (days)
Questionnaire Questionnaire
AB A B
Analgesics 9 (8.0) 21 (17.1) 3 2
Antibiotics 2 (5.9) 4 (21.0) 7 7
Antifungals 1 (4.5) 4 (36.4) 14 7
Antiparasitics 2 (15.4) 0 (0.0) 3 3
Antimalarials 0 (0.0) 2 (40.0) 3.5 1
Vitamins 3 (7.9) 7 (25.0) 15 7
Antiasthmatics 0 (0.0) 3 (30.0) 3.5 15
Antihistamines 4 (11.8) 13 (38.2) 4 3
Contraceptives * 2 (14.3) 0 (0.0) 30 † 30 †
Antitussives 0 (0.0) 0 (0.0) 5 10.5
Antacids 1 (5.0) 2 (20.0) 3 4.5
* Information on the use of contraceptives refers only to the female participants; † questionnaire completion examples included oral contraceptives 
with an exposure period defined as daily, which probably induced respondents to frame a 30-day duration of treatment.
Table 6: Information about the medicines used under medical advice during the previous month, according to the type of 
questionnaire.
Missing information regarding
medical advice, n (%)
Subjects who had used at least one medicine under medical advice, n (%)
Questionnaire Questionnaire
AB A B
Analgesics 5 (4.4) 15 (11.8) 34 (31.2) 22 (19.6)
Antibiotics 2 (5.9) 3 (15.8) 22 (68.8) 13 (81.3)
Antifungals 0 (0.0) 3 (27.3) 16 (72.7) 5 (62.5)
Antiparasitics 0 (0.0) 0 (0.0) 7 (53.9) 3 (60.0)
Antimalarials 0 (0.0) 2 (40.0) 3 (100.0) 1 (33.3)
Vitamins 2 (5.3) 8 (28.6) 19 (52.8) 13 (65.0)
Antiasthmatics 1 (14.3) 4 (40.0) 5 (83.3) 6 (100.0)
Antihistamines 1 (2.9) 8 (23.5) 7 (21.2) 7 (26.9)
Contraceptives * 1 (7.1) 3 (21.4) 11 (84.6) 8 (72.7)
Antitussives 1 (16.7) 0 (0.0) 2 (40.0) 2 (100.0)
Antacids 1 (5.0) 1 (10.0) 5 (26.3) 9 (32.1)
* Information on the use of contraceptives refers only to the female participants.BMC Medical Research Methodology 2009, 9:45 http://www.biomedcentral.com/1471-2288/9/45
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"flu or cold", we opted to analyze these groups together,
overcoming the potential misclassification.
No records were available to check the reported drug uti-
lization against the prescribed and non-prescribed drug
data, so no inferences could be drawn about the absolute
validity of exposure recall using questionnaires A or B.
However, studies comparing questionnaires with phar-
macy data as a gold standard have shown that drug-ori-
ented questionnaires yield better agreement than data
collected by open-ended questions [24,21], and the
design used for questionnaire A is expected to provide
more accurate estimates of drug utilization [18,21]. Also,
several studies have indicated that in drug utilization
studies the prevalence estimates obtained from question-
naire surveys are more reliable than information retrieved
from medical or pharmacy records, especially for assess-
ing over-the-counter drugs and medication misuse
[1,22,25-27]. Self-medication reports may be a useful
instrument, together with medical prescriptions and phar-
macy records, for measuring the efficacy of the drugs used
[28].
A concern when using a long questionnaire such as ver-
sion A is the burden that it imposes to the participant,
requiring a long time to answer the questions, which may
result in a larger proportion of refusals and in missing
data among respondents [7]. On the other hand, the phys-
ical layout of a questionnaire is important for increasing
response rates as it is sometimes easier to complete a ques-
tionnaire that, despite being longer, is clearer in structure
[29]. In our study, the time taken by the participants to
complete each questionnaire version could not be quanti-
fied, but the longer version is not necessarily expected to
take more time to complete as it does not differ from the
shorter one in the level of detail required. Also, the indi-
cation-oriented questions in version A may have been per-
ceived as easier to answer because they were more
structured, facilitating recall of previous treatments. The
proportion of refusals was low and similar for both ques-
tionnaire versions (1.7% for version A and 2.1% for ver-
sion B), probably because the questionnaires were
completed in the classroom. Therefore, in the present
study, missing information may be a better indicator of
the acceptability of the questionnaire than the proportion
of refusals.
The proportion of subjects with missing information
about the duration of treatment or medical advice was
even lower among those receiving the 4-page question-
naire, suggesting that both versions were well accepted by
the participants and that the layout of the longer ques-
tionnaire facilitated more complete recall.
We found that a substantial proportion of students used
medicines without medical advice, which would not be
identified in a study based on doctor-generated or phar-
macy-based prescription records. This finding has impli-
cations for studies relying on such databases and raises the
concern that such information includes false positive
«exposures» (prescriptions issued or completed but not
consumed).
In self-administered questionnaires, the first options in a
list of answering options are more likely to be chosen
(response choice order effects [6]). We could eventually
expect a similar phenomenon in the examples provided in
questionnaire B, or question order effects in questionnaire
A. The former would lead to larger differences between
questionnaire versions, the latter to smaller differences.
However, no consistent pattern was observed across the
last groups provided as examples (version B) or specifi-
cally asked (version A), and the different characteristics of
the last indications/pharmacological groups preclude
such an interpretation of the findings.
Conclusion
Our results add to previous research by demonstrating
that questionnaire structure and layout contribute to dif-
ferences in recall of pharmacological treatments, even
when the content of the questionnaire and the type of
questions are virtually the same. We also demonstrated
that a larger questionnaire does not necessarily lead to less
complete recall.
Future research on this topic should assess the impact of
data collection instruments across populations with dif-
ferent patterns of medicine utilization and ability to recall
usage over different periods.
For a proper interpretation of data from drug utilization
studies it is essential to take into account the characteris-
tics of the instruments used for data collection, and their
potential impact on the validity of the estimates for differ-
ent pharmacological groups and across settings.
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